Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Nathenson, MD
USWM CT, LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Ciusss de L'Est-de-Lile-de-Montreal
Montreal, Quebec, Canada
- Centre Léon Bérard
Lyon, France
- Chu de Bordeaux Gh Sud Hôpital Haut Lévêque
Pessac, France
- Fondazione Irccs Instituto Nazionale Dei Tumori
Milan, Lombardy, Italy
- Ircss Istituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy
- the Netherlands Cancer Institute
Amsterdam, Netherlands
- Hospital Santa Creu Y Sant Pau
Barcelona, Spain
- Ico Duran Y Reynals L'Hospitalet de Llobrega
Hospitalet de Llobregat, Barcelona, Spain
- Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
- Hospital Virgen del Rocio
Seville, Spain
- Royal Marsden Hospital
London, United Kingdom
- University College Hospital-London
London, United Kingdom
- Christie Hospital Nhs Foundation Trust
Manchester, United Kingdom
- City of Hope National Medical Center
Duarte, California, United States
- Stanford Hospital and Clinics
Stanford, California, United States
- Sarah Cannon Research Institute
Denver, Colorado, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- University of Chicago
Chicago, Illinois, United States
- University of Iowa College of Medicine
Iowa City, Iowa, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- University of Michigan Medical Center
Ann Arbor, Michigan, United States
- Minnesota Oncology Hematology
Minneapolis, Minnesota, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Washington University
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ohio State University-Columbus
Columbus, Ohio, United States
- Oregon Health and Science University
Portland, Oregon, United States
- University of Pittsburgh, Hillman Cancer Centre
Pittsburgh, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- University of Utah
Salt Lake City, Utah, United States
- Virginia Commonwealth University
Richmond, Virginia, United States
- Fred Hutchinson Cancer Research
Seattle, Washington, United States
- Froedtert Hospital
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2019
- Primary completion
- 1 Mar 2024
- Completion
- 31 Jul 2026
- Last update posted
- 17 Apr 2026
- Registered enrollment
- 103
- Registry id
- NCT03967223
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.